News & Presentations

UPCOMING EVENTS

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – January

AR-13324-CS208 Japan Phase 2 Study Topline Results

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 24, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update
Conference Call and Webcast Today, February 20 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Feb. 20, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 18, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 13, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
TOP